BioSpace News Archive

- Subgroup analysis of Phase 2 CHARMS study shows rapid resolution of macroscopic hematuria in patients with virus-associated hemorrhagic cystitis treated with Viralym-M - Real world claims data analyses demonstrate worse clinical outcomes, and significantly higher healthcare costs and health resource utilization in allogeneic HSCT recipients with virus-associated hemorrhagic cystitis and dsDNA viral infections

– Reports Revenues of $1.6 Million Compared with $634,000 in the Year-Ago Period and $314,000 in the Fourth Quarter of Fiscal 2020 – - Leverages EUA-Authorized Assay’s Ability to Discriminate for Certain SARS-CoV-2 Variants to Pursue Market for Genomic Surveillance, Receives Initial Orders –

GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company’s financial performance starting at 4:30 p.m. ET on the same day.

Today, the Steinberg Diagnostic Medical Imaging Group (SDMI) and Nevada-based design-build general contractor, SR Construction, officially broke ground on the tenth SDMI facility in southern Nevada.

OTIVIDEX ® Phase 3 trial results in Ménière’s disease expected by end of February OTO-313 Phase 2 trial in tinnitus planned to start in first quarter of 2021 with top-line results expected in mid-2022 OTO-413 Phase 1/2 trial expansion in hearing loss expected to start in second quarter of 2021 with results anticipated in mid-2022 Conference call and webcast today at 4:30 p.m. ET

Helio Health, an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced its participation in the 10 th Annual SVB Leerink Global Healthcare Conference, which takes place February 22-26, 2021 .

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming SVB Leerink 10th Annual Global Healthcare Conference. A webcast

Protalix BioTherapeutics, Inc. (NYSE American: PLX, TASE: PLX) (the “Company”), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system,

Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company

Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, today announced the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $19.00 per share.